Evidence map›Paper›PMID 38910595›Full record

ArticleJournal of scleroderma and related disorders2024

Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologists.

María Paula Álvarez-Hernández, Yannick Allanore, Ivo Andrade, Maya H Buch, Gerry Coghlan, Francesco Del Galdo, Christopher P Denton, Dinesh Khanna, David G Kiely, John D Pauling and 2 more

Abstract read
In one paragraph

Article in Journal of scleroderma and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

María Paula Álvarez-HernándezDepartment of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain.ORCID https://orcid.org/0000-0002-9972-1312
Yannick AllanoreDepartment of Rheumatology, Cochin Hospital, APHP, Université Paris Cité, Paris, France.
Ivo AndradeDepartment of Echocardiography, Manchester University NHS Foundation Trust, Manchester, UK.
Maya H BuchDivision of Musculoskeletal and Dermatological Sciences and Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Gerry CoghlanNational Pulmonary Hypertension Service, Royal Free Hospital, London, UK.
Francesco Del GaldoLeeds Institute of Rheumatic and Musculoskeletal Medicine and Biomedical Research Centre, University of Leeds, Leeds, UK.ORCID https://orcid.org/0000-0002-8528-2283
Christopher P DentonCentre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital, London, UK.ORCID https://orcid.org/0000-0003-3975-8938
Dinesh KhannaScleroderma Program, University of Michigan, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0001-6822-3401
David G KielyNational Pulmonary Hypertension Service, Royal Hallamshire Hospital, Sheffield, UK.
John D PaulingDepartment of Rheumatology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.ORCID https://orcid.org/0000-0002-2793-2364
Sheila RamjugDepartment of Respiratory Medicine, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Michael HughesDivision of Musculoskeletal and Dermatological Sciences and Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The objectives were to explore rheumatologists' current clinical screening practices of pulmonary arterial hypertension in patients with systemic sclerosis in the United Kingdom and to identify barriers to screening and consider potential solutions. Methods: A survey of 31 questions was developed and included six sections: clinician demographics, the importance of screening, screening practices, barriers to screening, treatment and patient education. The survey was disseminated among rheumatologists working in the United Kingdom. Results: Forty-four rheumatologists working in the United Kingdom participated in the study, and the majority completed all the questions. Around one-third (37.0%) worked in specialised systemic sclerosis units (university or general hospitals (54.5% and 45.4%, respectively)). The majority recognised that systemic sclerosis-pulmonary arterial hypertension is a major cause of morbidity and mortality. Over half (60.0%) reported using the DETECT algorithm to screen for systemic sclerosis-pulmonary arterial hypertension, although other algorithms were also sometimes used. All of the respondents utilised transthoracic echocardiogram, and almost all (95.0%) performed pulmonary function tests for screening purposes. Various challenges and barriers were identified relating to systemic sclerosis-pulmonary arterial hypertension screening, with the difficulty in interpreting results from other hospitals and extended wait times for diagnostic tests being the most reported (76.0% and 74.0%, respectively). Most respondents agreed that access to key investigations (87.0%), ongoing clinician education (82.0%), multidisciplinary meetings (79.5%) and a better understanding of proposed screening algorithms (79.5%) could be potential solutions. Conclusion: Screening patients with systemic sclerosis for pulmonary arterial hypertension is crucial to improve survival, but variable practices exist among UK rheumatologists. Solutions include educating healthcare professionals on guidelines, sharing information between centres and integrating care services.

Indexed as

pulmonary arterial hypertensionrheumatologistssclerodermascreeningSystemic sclerosisThe United Kingdom

Identifiers

PMID38910595
PMCPMC11188845

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.